NeoGenomics, Inc. Company Research Report

Company Overview

• Name: NeoGenomics, Inc.

• Mission: Save lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. They aim to create better, more hopeful futures for people living with cancer.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Chris Smith, Chief Executive Officer

• Jeff Sherman, Chief Financial Officer

• Warren Stone, Chief Commercial Officer

• Melody Harris, Chief Operations Officer & President, Informatics

• Ali Olivo, Executive Vice President, General Counsel & Business Development

• Hutan Hashemi, JD, Chief Compliance Officer

• Nathan Montgomery, MD, PhD, Vice President, Medical Services

• Gary Passman, Chief Culture Officer

• Kareem Saad, Head of Strategy and Transformation

• Headquarters: 9490 NeoGenomics Way, Fort Myers, FL 33912

• Number of Employees: No information is available.

• Revenue: Consolidated revenue for Q3 2024 was $168 million, a 10% increase from the same period in 2023.

• Known For: NeoGenomics specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus globally for physicians to aid in diagnosing and treating cancer.

Products

NEO | AML Express™

• Description: Offers a comprehensive NGS-based assessment with a class-leading turnaround time.

• Key Features: Provides actionable diagnostic and prognostic information with one order and one specimen.

Early-Stage NSCLC Panel

• Description: A therapy selection panel specifically for early-stage NSCLC patients.

• Key Features: Offers testing for relevant biomarkers in early-stage NSCLC.

Neo Comprehensive™ - Heme Cancers

• Description: Analyzes 433 genes associated with various hematologic malignancies in a single assay.

• Key Features: Detects DNA and RNA alterations associated with myeloid and lymphoid lineages.

Neo Comprehensive™ - Solid Tumor

• Description: Covers 517 cancer-relevant genes with MSI/TMB using DNA and RNA.

• Key Features: Detects SNVs, indels, CNVs, fusions, and splice variants with results delivered in 10 days.

Neo Comprehensive™ - Myeloid Disorders

• Description: A comprehensive genomic profile analyzing 164 genes relevant in myeloid neoplasms.

• Key Features: Offers diagnostic evaluation, prognosis, risk stratification, and therapy guidance.

NeoTYPE® DNA & RNA – Lung

• Description: A targeted tissue-based assay featuring RNA-based fusion detection.

• Key Features: Offers results in 10 days with a simple, easy-to-interpret report.

Recent Developments

Financial Performance

• Third Quarter 2024 Highlights:

• Consolidated revenue increased by 10% to $168 million.

• Clinical Services revenue increased by 14% to $146 million.

• Advanced Diagnostics revenue decreased by 10% to $22 million.

• Net loss decreased by 4% to $18 million.

• Adjusted EBITDA increased 305% to $13 million.

New Products and Features

• AML Express: Launched for the rapid genetic profiling of Acute Myeloid Leukemia.

• Neo Comprehensive™ Solid Tumor Test: Received approval from New York State.

Strategic Moves

• Board of Directors: Felicia Williams was appointed, adding extensive experience in finance, accounting, and risk management.

Partnerships and Events

• Healthcare Conference: NeoGenomics participated in the Piper Sandler 36th Annual Healthcare Conference, with executives engaging in discussions on December 5, 2024.

---

This report synthesizes available data on NeoGenomics, Inc., focusing on their corporate structure, product offerings, recent financial performance, and strategic developments.